Broader tumor-stromal studies show that CAFs secrete IGF/IGFBP ligands that rewire signaling and drug response in adjacent cancer cells, supporting a mechanistic niche for stromal IGFBP-6 in liver tumor microenvironments [40]. The gene discussed is IGF1; the disease is cancer.